Analysts Offer Predictions for Caribou Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:CRBU)

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Research analysts at Leerink Partnrs increased their Q3 2024 earnings per share (EPS) estimates for Caribou Biosciences in a note issued to investors on Tuesday, August 6th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earnings of ($0.44) per share for the quarter, up from their previous forecast of ($0.47). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.80) per share. Leerink Partnrs also issued estimates for Caribou Biosciences’ Q4 2024 earnings at ($0.45) EPS, FY2024 earnings at ($1.77) EPS, FY2025 earnings at ($1.69) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.74) EPS and FY2028 earnings at ($0.60) EPS.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.04. Caribou Biosciences had a negative return on equity of 33.42% and a negative net margin of 345.05%. The firm had revenue of $3.46 million during the quarter, compared to analysts’ expectations of $3.31 million.

Other analysts have also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a research report on Wednesday, July 17th. Truist Financial reiterated a “buy” rating and set a $19.00 price objective on shares of Caribou Biosciences in a research report on Thursday, May 16th. Evercore ISI cut Caribou Biosciences from an “outperform” rating to an “inline” rating and reduced their price objective for the company from $13.00 to $3.00 in a research report on Monday, June 3rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $14.00 price objective on shares of Caribou Biosciences in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Caribou Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Caribou Biosciences Price Performance

CRBU stock opened at $1.94 on Friday. The stock has a market capitalization of $175.22 million, a P/E ratio of -1.34 and a beta of 2.30. Caribou Biosciences has a 1-year low of $1.50 and a 1-year high of $8.33. The business has a fifty day moving average price of $1.98 and a 200-day moving average price of $4.02.

Institutional Trading of Caribou Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of CRBU. China Universal Asset Management Co. Ltd. boosted its stake in shares of Caribou Biosciences by 66.5% in the first quarter. China Universal Asset Management Co. Ltd. now owns 17,024 shares of the company’s stock worth $88,000 after acquiring an additional 6,798 shares during the period. Entropy Technologies LP bought a new position in shares of Caribou Biosciences in the first quarter worth about $113,000. Raymond James Financial Services Advisors Inc. bought a new position in shares of Caribou Biosciences in the fourth quarter worth about $150,000. Bayesian Capital Management LP bought a new position in shares of Caribou Biosciences in the first quarter worth about $151,000. Finally, Walleye Trading LLC bought a new position in shares of Caribou Biosciences in the first quarter worth about $155,000. Hedge funds and other institutional investors own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.